Sue Hughes
Medical Journalist at WebMD
Medical journalist @theheartorg since 2000. And Medscape Neurology since 2012.
Articles
-
1 week ago |
medscape.com | Sue Hughes
HELSINKI — In patients with large vessel occlusion stroke treated within 4.5 hours of symptom onset, outcomes were better in those who received the thrombolytic tenecteplase prior to endovascular therapy than in those who underwent endovascular treatment alone. Results from the BRIDGE-TNK trial showed that patients who received tenecteplase had a significantly higher likelihood of achieving functional independence at day 90.
-
1 week ago |
medscape.com | Sue Hughes
New data from subgroup analyses of trials evaluating endovascular treatment in patients with stroke due to occlusions of distal or medium arteries has given some hope that there may be a population who could benefit from such an approach.
-
2 weeks ago |
medscape.com | Sue Hughes
HELSINKI, Finland — Less intensive monitoring of patients with acute ischemic stroke who have undergone thrombolysis appeared to be safe in new findings that challenge current guidelines. The large international OPTIMISTmain trial showed that less frequent monitoring of vital signs and neurologic function during the first 24 hours did not compromise recovery or increase the risk for serious adverse events compared with standard protocols.
-
1 month ago |
francais.medscape.com | Sue Hughes
CHICAGO – Le traitement prolongé par apixaban à dose réduite est tout aussi efficace que la dose élevée pour prévenir les récidives de thromboembolie veineuse (TEV) chez les patients atteints d'un cancer actif qui ont suivi un traitement anticoagulant pendant au moins six mois après la formation d'un caillot, et entraîne un taux plus faible de saignements significatifs d'un point de vue clinique, selon l'étude API-CAT.
-
1 month ago |
medscape.com | Sue Hughes
For patients who experience excessive bleeding during cardiac surgery, four-factor prothrombin complex concentrate (4F-PCC), a blood product that contains clotting factors, is significantly more effective at stopping bleeding than frozen plasma and causes fewer adverse effects, the FARES-II trial showed.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 279
- Tweets
- 37
- DMs Open
- No
Anyone know what is happening with @LycamobileUK I can’t access my account on the App and they have not renewed my account so I have no service. Can’t seem to even talk to the bot. Anyone have any updates?
Kastelein waxes lyrical on PCSK9 antibodies at #AHA12. See my updated article on @theheartorg http://t.co/fckmhfz0
"LDL levels under 30mg/dL will be seen with anti-PCSK9 antibodies". See updated article on http://t.co/pV8gSPFY. #AHA2012